Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the presentation of investigational new drug (IND)-enabling data that support the company’s lead inhibitory neuronal cell therapy candidate, NRTX-1001, which has entered a first-in-human clinical trial for the treatment of drug-resistant focal epilepsy.
June 17, 2022
· 5 min read